Long-acting β-agonist prescribing in people with asthma in primary care

Daniel R. Morales*, Catherine Miriam Jackson, Shona Fielding, Bruce Guthrie

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Long-acting beta 2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

Original languageEnglish
Pages (from-to)192-194
Number of pages3
JournalThorax
Volume68
Issue number2
Early online date1 Sept 2012
DOIs
Publication statusPublished - Feb 2013

Cite this